These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35835296)

  • 1. SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.
    Wijtvliet VPWM; Verheyden S; Depreter B; Heylen C; Coeman E; Abrams S; De Winter BY; Massart A; Hellemans R; Pipeleers L; Claas FHJ; Ariën KK; Wissing KM; Abramowicz D; Ledeganck KJ
    Transpl Immunol; 2022 Oct; 74():101670. PubMed ID: 35835296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.
    McCune TR; Bray RA; Baran DA; Toepp AJ; Forte SJ; Gilgannon LT; Williams T; Chen S; Sadr H; Gebel HM; Herre JM
    Transpl Immunol; 2022 Dec; 75():101722. PubMed ID: 36152939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
    Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
    Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
    Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
    CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.
    Cappuccilli M; Semprini S; Fabbri E; Fantini M; Bruno PF; Spazzoli A; Righini M; Flachi M; La Manna G; Sambri V; Mosconi G
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888612
    [No Abstract]   [Full Text] [Related]  

  • 7. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
    Graninger M; Stumpf J; Bond G; Görzer I; Springer DN; Kessel F; Kröger H; Frank K; Tonn T; Hugo C; Puchhammer-Stöckl E
    J Clin Virol; 2023 May; 162():105428. PubMed ID: 36989730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients.
    Crane C; Phebus E; Ingulli E
    Pediatr Nephrol; 2022 Feb; 37(2):449-453. PubMed ID: 34522992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
    Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
    Front Immunol; 2022; 13():838985. PubMed ID: 35281011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
    Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
    Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
    Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
    J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
    Longlune N; Nogier MB; Miedougé M; Gabilan C; Cartou C; Seigneuric B; Del Bello A; Marion O; Faguer S; Izopet J; Kamar N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1704-1709. PubMed ID: 34057463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
    Rincon-Arevalo H; Choi M; Stefanski AL; Halleck F; Weber U; Szelinski F; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Potekhin A; Chen Y; Burmester GR; Eckardt KU; Guerra GM; Durek P; Heinrich F; Ferreira-Gomes M; Radbruch A; Budde K; Lino AC; Mashreghi MF; Schrezenmeier E; Dörner T
    Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34131023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.